Treatment for Axillary Vein DVT in Patient on Plavix Post-Coronary Stenting
Continue clopidogrel (Plavix) 75 mg daily and add therapeutic anticoagulation with a direct oral anticoagulant (DOAC) for at least 3 months to treat the axillary vein DVT. This dual therapy approach balances the critical need to prevent stent thrombosis while adequately treating the upper extremity deep vein thrombosis.
Rationale for Dual Therapy
The 2012 ACCP guidelines specifically address upper extremity DVT involving the axillary or more proximal veins, recommending therapeutic anticoagulation with LMWH or fondaparinux over IV UFH 1. While DOACs are not explicitly mentioned in this 2012 guideline, more recent evidence supports their use as first-line agents for VTE treatment.
The timing since your stent placement is the critical decision point:
If <12 Months Post-Stenting:
- Continue clopidogrel 75 mg daily - This is non-negotiable for stent thrombosis prevention 2, 3
- Add full-dose anticoagulation with a DOAC (rivaroxaban, apixaban, or edoxaban preferred)
- The 2024 ESC guidelines support continuation of P2Y12 inhibitor therapy when anticoagulation is added for other indications 3
If >12 Months Post-Stenting:
- You have more flexibility to stop clopidogrel and use anticoagulation alone 4
- However, given the established safety of continuing clopidogrel with anticoagulation in chronic coronary syndrome patients, continuation may still be reasonable
Specific Anticoagulation Regimen
DOAC selection (in order of preference):
- Rivaroxaban 15 mg twice daily for 21 days, then 20 mg once daily
- Apixaban 10 mg twice daily for 7 days, then 5 mg twice daily
- Edoxaban 60 mg once daily (after 5-10 days of parenteral anticoagulation)
The 2012 ACCP guidelines recommend a minimum of 3 months anticoagulation for axillary vein DVT 1. Since your DVT is not catheter-related and you don't have cancer, 3 months is the appropriate duration unless there are additional risk factors suggesting provoked vs unprovoked thrombosis.
Bleeding Risk Management
This combination increases bleeding risk - the 2006 AHA/ACC guidelines explicitly warn that warfarin combined with aspirin and/or clopidogrel increases bleeding risk and requires close monitoring 5. While this referred to warfarin, the principle applies to all anticoagulants. Research from 2004 showed a 9.2% bleeding rate with triple therapy (aspirin, clopidogrel, warfarin) after PCI 6.
Key monitoring points:
- Assess for signs of bleeding at 1 week, 1 month, and 3 months
- Check hemoglobin if any bleeding symptoms develop
- Avoid NSAIDs and other antiplatelet agents
- Consider PPI therapy for GI protection
Critical Pitfalls to Avoid
- Do NOT stop clopidogrel abruptly if <12 months post-stent - this dramatically increases stent thrombosis risk, which can be catastrophic 5, 7
- Do NOT use warfarin as first-line - DOACs have superior safety profiles and don't require INR monitoring
- Do NOT delay anticoagulation while awaiting specialist consultation - axillary DVT requires prompt treatment to prevent PE 1
- Do NOT use subtherapeutic "prophylactic" anticoagulation doses - full therapeutic anticoagulation is required for established DVT
Coordination with Cardiology
Contact the interventional cardiologist who placed the stent to:
- Confirm the exact stent type (bare metal vs drug-eluting) and timing
- Discuss whether the clinical scenario was ACS vs stable disease
- Determine if there are high-risk features (left main, bifurcation, multiple stents) that would favor continuing dual antiplatelet therapy longer
The 2020 ACC Expert Consensus specifically addresses this scenario, recommending stopping aspirin, continuing clopidogrel, and adding anticoagulation when VTE occurs in patients <6 months post-PCI 4.